Serum interleukin-2 receptor for the early diagnosis of rheumatoid arthritis

Clinical Rheumatology

Volumn 17, Issue 4, 1998, Pages 311-317

  Suenaga, Y ^a   Yasuda, M ^a,b   Yamamoto, M ^a   Nonaka, S ^a   Wada, T ^a   Shiokawa, S ^a   Nobunaga, M ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION BEPPU MEDICAL CENTER   (Japan)

Author keywords

Early diagnosis; Rheumatoid arthritis; Soluble interleukin 2 receptor

Indexed keywords

ANTIRHEUMATIC AGENT; AUROTHIOMALATE; C REACTIVE PROTEIN; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RHEUMATOID FACTOR;

ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ADULT; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FOLLOW-UP STUDIES; HUMANS; PREDICTIVE VALUE OF TESTS; PROBABILITY; RECEPTORS, INTERLEUKIN-2; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RHEUMATOID FACTOR; SOLUBILITY;

EID: 0031694536     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01451012     Document Type: Article

References (30)

1. Nathan JZ. Etiology and pathogenesis of rheumatoid arthritis. In: McCarty DJ, editor. Arthritis and allied conditions, 11th edn. Philadelphia: Lea & Febiger, 1989:659-73.
2. Wilske KR. Inverting the therapeutic pyramid: observations and recommendations on new directions in rheumatoid arthritis therapy based on the author's experience. Semin Arthritis Rheum 1993;23:11-8.
3. Iannuzzi L, Dawson N, Zein N, Kushner I. Does drug therapy slow radiographic deterioration in rheumatoid arthritis? N Engl J Med 1983;309:1023-8.
4. Luukaine K, Kajander R, Isomaki H. Effect of gold on progression of erosions in rheumatoid arthritis. Better results with early treatment. Scand J Rheumatol 1977;6:189-92.
5. The Australian Multicenter Clinical Trial Group. Sulfasalazine in early rheumatoid arthritis. J Rheumatol 1992;19:1672-7.
6. Multicenter Trial Group. A prospective five-year comparison of treatment which included penicillamine with that excluding penicillamine in early rheumatoid arthritis. Br J Rheumatol 1986;25:184-92.
7. Co-operating Clinics Committee of the American Rheumatism Association. A controlled trial of cyclophosphamide in rheumatoid arthritis. N Engl J Med 1970;283:883-9.
8. Nides SJ, Field EH. Transient rheumatoid factor positivity in acute human parvovirus B19 infection. Arch Intern Med 1988;148:2587-9.
9. Rubin LA, Nelson DL. The soluble interleukin-2 receptor: biology, function and clinical application. Ann Intern Med 1990;113:619-27.
10. Symons JA, Wood NC, Di Giovine FS, Duff GW. Soluble IL-2 receptor in rheumatoid arthritis. Correlation with disease activity, IL-1 and IL-2 inhibition. J Immunol 1988;141:2612-8.
11. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
12. Ropes MW, Bennett GA, Cobb S, Jacox R, Jessar RA. 1958 revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis 1958;9:175-6.
13. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA 1949:140:659-62.
14. Sharp JT, Young DY, Bluhm GB, et al. How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? Arthritis Rheum 1985;28:1326-35.
15. Anderson JJ, Felson DT, Meenan RF, Williams JH. Which traditional measures should be used in rheumatoid clinical trials? Arthritis Rheum 1989;32:1093-9.
16. Finals RS, Masi AT, Larsen RA. Subcommittee for Criteria of Remission in Rheumatoid Arthritis of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981;24.1303-15.
17. Tunn EJ, Bacon PA. Differentiating persistent from self-limiting symmetrical synovitis in an early arthritis clinic. Br J Rheumatol 1993;32:97-103.
18. Brook A, Corbett M. Radiographic changes in early rheumatoid disease. Ann Rheum Dis 1977;36:71-3.
19. Campen DH, Horwitz DA, Quismorio FP Jr, Ehresmann GR, Martin WJ. Serum levels of interleukin-2 receptor and activity of rheumatic diseases characterized by immune system activation. Arthritis Rheum 1988;31:1358-64.
20. Rubin, LA, Snow KM, Kurman CC, Nelson DL, Keystone EC. Serial levels of soluble interleukin 2 receptor in peripheral blood of patients with rheumatoid arthritis: correlations with disease activity. J Rheumatol 1990;17:597-602.
21. Polisson RP, Dooley MA, Dawson DV, Pisetsky DS. Interleukin-2 receptor levels in the sera of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 1994;37:50-6.
22. Barrera P, Haagsma CJ, Boerbooms AM, Van Riel PL, Borm GF, Van de Putte LB, Van der Meer JW. Effect of methotrexate alone or in combination with sulphasalazine on the production and circulation of cytokines and their antagonists. Longitudinal evaluation in patients with rheumatoid arthritis. Br J Rheumatol 1995;34:747-55.
23. Keystone EC, Snow KM, Bombardier C, Chang CH, Nelson DL, Rubin LA. Elevated soluble interleukin-2 receptor levels in the sera and synovial fluids of patients with rheumatoid arthritis. Arthritis Rheum 1988;31:844-9.
24. Crilly A, Madhok R, Watson J, Capell HA. Serum concentration of soluble interleukin 2 receptor in patients with rheumatoid arthritis: effect of second line drugs. Ann Rheum Dis 1993;52:58-60.
25. Kirkham BW, Davison SC, Corkill MM, Barbatis C, Pnayi GS. Serial soluble interleukin 2 receptor levels in rheumatoid arthritis: differences in response to glucocorticoid treatment and crysotherapy. J Rheumatol 1993;20:935-9.
26. Salaffi F, Carotti M, Cervini C. Serum soluble interleukin-2 receptor levels in rheumatoid arthritis: effect of methotrexate, sulphasalazine and hydroxychloroquine therapy. Clin Rheumatol 1995;14:458-63.
27. Weyand CM, Hicok KC, Conn DL, Ooronzy JJ. The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann Intern Med 1992;117:801-6.
28. Paimela L, Gripenberg M, Kurki P, Leirisalo-Repo M. Antikeratin antibodies: diagnostic and prognostic markers for early rheumatoid arthritis. Ann Rheum Dis 1992;51:743-6.
29. Eberhardt K, Grubb R, Johnson U, Pettersson H. HLA-DR antigens, Gm allotypes and antiallotypes in early rheumatoid arthritis - their relation to disease progression. J Rheumatol 1993;20:1825-9.
30. Terato K, Shimozuri Y, Katayama K, et al. Specificity of antibodies to type II collagen in rheumatoid arthritis. Arthritis Rheum 1990;33:1493-1500.